vimarsana.com

Latest Breaking News On - Prnewswire oncosec medical incorporated - Page 1 : vimarsana.com

OncoSec Announces Closing of $1 33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral.

New yorkUnited statesMike moyerOncosec medical incorporated the companyCompany or oncosecExchange commissionCompany annual report on formOncosec medical incorporatedPrnewswire oncosec medical incorporatedHc wainwright coCompany contactSec medical incorporatedSecurities actOncosec medicalPrivate securities litigation reform actAnnual report

OncoSec Announces $1 33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral.

United statesNew yorkMike moyerCompany contactPrnewswire oncosec medical incorporatedCompany or oncosecHc wainwright coExchange commissionOncosec medical incorporated the companyCompany annual report on formOncosec medical incorporatedSec medical incorporatedSecurities actOncosec medicalPrivate securities litigation reform actAnnual report

OncoSec Announces $1 33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

EWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ OncoSec Medical Incorporated , a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient s. | June 12, 2023

New yorkUnited statesMike moyerHc wainwright coCompany contactCompany or oncosecOncosec medical incorporated the companyCompany annual report on formOncosec medical incorporatedExchange commissionPrnewswire oncosec medical incorporatedSec medical incorporatedSecurities actOncosec medicalPrivate securities litigation reform actAnnual report

OncoSec Receives $3 49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program

/PRNewswire/ OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral.

New jerseyUnited statesMike moyerOncosec medical incorporatedSecurities exchange commissionCompany annual report on formPrnewswire oncosec medical incorporatedCompany or oncosecCompany contactTechnology business tax certificate transfer programOncosec medical incorporated the companyJersey economic development authoritySec medical incorporatedNew jersey economic development authorityBusiness tax certificate transfer programChief executive officer

OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

EWING, N.J. and SAN DIEGO, April 11, 2023 /PRNewswire/ OncoSec Medical Incorporated , a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient s. | April 11, 2023

United statesNew yorkMike moyerCompany annual report on formCompany or oncosecOncosec medical incorporatedOncosec medical incorporated the companyPrnewswire oncosec medical incorporatedCompany contactExchange commissionHc wainwright coSec medical incorporatedSecurities actOncosec medicalPrivate securities litigation reform actAnnual report

vimarsana © 2020. All Rights Reserved.